Financial PerformanceAgilent Technologies reported F4Q sales and EPS that beat expectations, with core sales in ACG growing by 5%.
Growth PotentialThe CDMO business is poised for significant growth through acquisitions like BIOVECTRA and capacity upgrades, with long-term revenue potential exceeding $1B.
Market PositionAgilent has an upbeat outlook on the PFAS market, highlighting its leading position in this growing end market.